REFERENCES
1. Liberti MV, Locasale JW. The warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41:211-8.
2. Vijayanathan Y, Ho IAW. The impact of metabolic rewiring in glioblastoma: the immune landscape and therapeutic strategies. Int J Mol Sci. 2025;26:669.
3. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149:1060-72.
4. Chen X, Kang R, Kroemer G, Tang D. Broadening horizons: the role of ferroptosis in cancer. Nat Rev Clin Oncol. 2021;18:280-96.
5. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399-416.
6. Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599-620.
7. Koncošová M, Vrzáčková N, Křížová I, et al. Inhibition of mitochondrial metabolism leads to selective eradication of cells adapted to acidic microenvironment. Int J Mol Sci. 2021;22:10790.
8. Li H, Wu Y, Ma Y, Liu X. Interference with ENO2 promotes ferroptosis and inhibits glycolysis in clear cell renal cell carcinoma by regulating Hippo-YAP1 signaling. Oncol Lett. 2024;28:443.
9. Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017;13:81-90.
10. Doll S, Proneth B, Tyurina YY, et al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2017;13:91-8.
11. Tesfay L, Paul BT, Konstorum A, et al. Stearoyl-CoA desaturase 1 protects ovarian cancer cells from ferroptotic cell death. Cancer Res. 2019;79:5355-66.
13. Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer. Cancer Cell. 2019;35:830-49.
14. Sharma A, Flora SJS. Positive and negative regulation of ferroptosis and its role in maintaining metabolic and redox homeostasis. Oxid Med Cell Longev. 2021;2021:9074206.
15. Kong Y, Li J, Lin R, et al. Understanding the unique mechanism of ferroptosis: a promising therapeutic target. Front Cell Dev Biol. 2023;11:1329147.
16. Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014;16:1180-91.
17. Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. 2019;575:693-8.
18. Kraft VAN, Bezjian CT, Pfeiffer S, et al. GTP cyclohydrolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci. 2020;6:41-53.
19. Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer. Nat Rev Cancer. 2022;22:381-96.
20. Efimova I, Catanzaro E, Van der Meeren L, et al. Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity. J Immunother Cancer. 2020;8:e001369.
21. Li Y, Liu Y, Zhao Y, et al. Ferroptosis in lung cancer: emerging mechanisms, therapeutic targeting, and immune modulation. Cell Signal. 2026;141:112403.
22. Li S, Li Z. The crosstalk between ferroptosis and the immune system in urological cancers: mechanisms, prognostic value, and therapeutic implications. Crit Rev Oncol Hematol. 2026;218:105070.
23. Chen X, Kang R, Kroemer G, Tang D. Ferroptosis in infection, inflammation, and immunity. J Exp Med. 2021:218.
24. Colegio OR, Chu NQ, Szabo AL, et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. 2014;513:559-63.
25. Zhu JF, Guo DP, Lv HN, Liang ZY, Song J, Zeng W. Histone lactylation-mediated up-regulation of IGF2BP2 enhances ferroptosis resistance via Nrf2 in colorectal cancer. Clin Transl Med. 2025;15:e70551.
26. Ma J, Zhang H, Chen Y, Liu X, Tian J, Shen W. The role of macrophage iron overload and ferroptosis in atherosclerosis. Biomolecules. 2022;12:1702.
27. Kang R, Zeng L, Zhu S, et al. Lipid peroxidation drives gasdermin d-mediated pyroptosis in lethal polymicrobial sepsis. Cell Host Microbe. 2018;24:97-108.e4.
28. Wang Y, Wan R, Peng W, Zhao X, Bai W, Hu C. Quercetin alleviates ferroptosis accompanied by reducing M1 macrophage polarization during neutrophilic airway inflammation. Eur J Pharmacol. 2023;938:175407.
29. Chen P, Wang D, Xiao T, et al. ACSL4 promotes ferroptosis and M1 macrophage polarization to regulate the tumorigenesis of nasopharyngeal carcinoma. Int Immunopharmacol. 2023;122:110629.
30. Chen P, Lv X, Zheng Z. Gigantol exerts anti-lung cancer activity by inducing ferroptosis via SLC7A11-GPX4 axis. Biochem Biophys Res Commun. 2024;690:149274.
31. Guo F, Zong S, Zhang X, et al. Ferroptosis and metastasis: molecular checkpoints, microenvironmental dynamics, and therapeutic opportunities. Mol Cancer. 2026:25.
32. Zhang J, Meng X, Zhao X, et al. Tumor-associated macrophages educated by IGSF9 exhibit a senescence-associated secretory phenotype to promote tumor immune escape. J Immunother Cancer. 2026;14:e012889.
33. Qian Z, Zhang Z, Bai W, et al. Immunometabolic crosstalk between tumor- associated macrophages and ferroptotic cancer cells: mechanisms, regulation, and therapeutic applications. Front Immunol. 2025;16:1628142.
34. Luo X, Gong HB, Gao HY, et al. Oxygenated phosphatidylethanolamine navigates phagocytosis of ferroptotic cells by interacting with TLR2. Cell Death Differ. 2021;28:1971-89.
35. Dai E, Han L, Liu J, et al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy. 2020;16:2069-83.
36. Kim R, Taylor D, Vonderheide RH, Gabrilovich DI. Ferroptosis of immune cells in the tumor microenvironment. Trends Pharmacol Sci. 2023;44:542-52.
37. Srivastava N, Wan X. From damage signals to immune modulators: oxidized lipids in immunometabolic inflammation. J Lipid Res. 2026;67:100990.
38. Mo Y, Zou Z, Chen E. Research progress on ferroptosis regulation in tumor immunity of hepatocellular carcinoma. J Zhejiang Univ. ;53:715-25.
39. Cao J, Chen K, Hu K, et al. USP2-mediated PPARγ stabilization promotes hepatocellular carcinoma progression and M2 macrophage polarization via oleic acid. J Immunother Cancer. 2025;13:e012721.
40. Zhu LL, Wu Z, Li RK, et al. Deciphering the genomic and lncRNA landscapes of aerobic glycolysis identifies potential therapeutic targets in pancreatic cancer. Int J Biol Sci. 2021;17:107-18.
41. Zhang P, Li C, Li F, Wu J, Hu K, Huang H. Novel multi-omics analysis revealing metabolic heterogeneity of breast cancer cell and subsequent development of associated prognostic signature. Transl Oncol. 2025;59:102444.
42. Li D, Wang Z, Yu Q, et al. Tracing the evolution of sex hormones and receptor-mediated immune microenvironmental differences in prostate and bladder cancers: from embryonic development to disease. Adv Sci. 2025;12:e2407715.
43. Liu H, Yang W, Jiang J. Targeting tumor metabolism to augment CD8+ T cell anti-tumor immunity. J Pharm Anal. 2025;15:101150.
44. Wu L, Yang L, Sun J, et al. Synergistic changes in bystander CD8 and conventional CD4 T cells during neoadjuvant chemoimmunotherapy for non-small cell lung cancer reveal treatment response. Pathol Oncol Res. 2025;31:1612229.
45. Bhowmick S, Banerjee S, Shridhar V, Mondal S. Reprogrammed immuno-metabolic environment of cancer: the driving force of ferroptosis resistance. Mol Cancer. 2025;24:161.
46. Xiao H, Du X, Tao Z, et al. Taurine inhibits ferroptosis mediated by the crosstalk between tumor cells and tumor-associated macrophages in prostate cancer. Adv Sci. 2024;11:e2303894.
47. Zhao J, Xu B, Xiong Q, Feng Y, Du H. Erastin-induced ferroptosis causes physiological and pathological changes in healthy tissues of mice. Mol Med Rep. 2021;24:713.
48. Wu X, Wu Q, Wang Y, et al. Aqueous-soluble components of sporoderm-removed Ganoderma lucidum spore powder promote ferroptosis in oral squamous cell carcinoma. Chin J Cancer Res. 2023;35:176-90.
49. Wang W, Green M, Choi JE, et al. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569:270-4.
50. Zhou Z, Liu J, Li C, et al. Gallium nanoparticles‐mediated metalloimmunotherapy overcomes immunological tolerance induced by ferroptosis. Adv Funct Mater. 2026;36:e76579.
51. Fiorentino V, Pizzimenti C, Franchina M, et al. Programmed cell death ligand 1 immunohistochemical expression and cutaneous melanoma: a controversial relationship. Int J Mol Sci. 2024;25:676.
52. Zhan F, Hu Y, Jiang X, Fang Z. The progress of ferroptosis of immune cells in the tumor microenvironment and its impact on tumorigenesis and development. Immun Inflamm Dis. 2026;14:e70333.
53. Dai Y, Guo Z, Leng D, et al. Metal-coordinated NIR-II nanoadjuvants with nanobody conjugation for potentiating immunotherapy by tumor metabolism reprogramming. Adv Sci. 2024;11:e2404886.
54. Chen Z, Huang H, Shen Y, et al. Targeting the exosomal CaMK2A-ZDHHC3-GPX4 pathway reprograms tumor-associated macrophages and enhances anti-PD-1/PD-L1 immunotherapy in gastric cancer. Int J Biol Sci. 2026;22:5659-84.
55. Huang A, Li Q, Shi X, et al. An iron-containing nanomedicine for inducing deep tumor penetration and synergistic ferroptosis in enhanced pancreatic cancer therapy. Mater Today Bio. 2024;27:101132.
56. Chen X, Li J, Kang R, Klionsky DJ, Tang D. Ferroptosis: machinery and regulation. Autophagy. 2021;17:2054-81.
